Recent Price Movement and Market Performance
Fortis Healthcare’s shares have experienced a notable dip over the past week, falling 5.87%, which is a sharper decline than the Sensex’s 3.33% drop in the same period. Although the stock has outperformed the broader market over longer horizons—delivering a remarkable 39.37% return in the last year and an impressive 219.99% over three years—the short-term momentum has turned negative. Year-to-date, the stock is down marginally by 0.62%, while the Sensex has fallen 8.98%, indicating relative resilience but recent weakness.
On 09-Mar, the stock underperformed its sector by 1.59%, marking the second consecutive day of losses and a cumulative decline of 4.65% over this brief period. Intraday, the share price touched a low of ₹857, representing a 3.98% drop from previous levels. This downward pressure is compounded by the stock trading below all key moving averages—5-day, 20-day, 50-day, 100-day, and 200-day—signalling a bearish technical outlook.
Our latest monthly pick, this Large Cap from Aluminium & Aluminium Products, is outperforming the market! See the analysis that helped our Investment Committee select this winner.
- - Market-beating performance
- - Committee-backed winner
- - Aluminium & Aluminium Products standout
Investor Participation and Liquidity
Investor engagement appears to be waning, with delivery volumes on 06 Mar falling by 26.28% compared to the five-day average, suggesting reduced buying interest. Despite this, liquidity remains adequate, with the stock supporting trade sizes of approximately ₹3.35 crores based on 2% of the five-day average traded value. This level of liquidity ensures that the stock remains accessible for institutional and retail investors alike, though the declining participation may be contributing to the recent price softness.
Fundamental Strengths Supporting Fortis Healthcare
On the positive side, Fortis Healthcare demonstrates a robust capacity to service its debt, with a low Debt to EBITDA ratio of 0.91 times, indicating manageable leverage. The company’s operating profit has exhibited exceptional growth, expanding at an annual rate of 115.19%, underscoring strong operational performance over the long term. Institutional investors hold a significant 57.17% stake, reflecting confidence from sophisticated market participants who typically conduct thorough fundamental analysis. This institutional backing has likely supported the stock’s consistent outperformance of the BSE500 index across the last three annual periods.
Challenges and Valuation Concerns
However, certain financial metrics raise caution. The company’s operating profit to interest coverage ratio stands at a relatively low 5.90 times, which may signal tighter margins for servicing interest expenses. The debt-equity ratio, at 0.34 times, is the highest among its peers, suggesting a comparatively elevated reliance on debt financing. Additionally, the debtors turnover ratio is at a low 8.29 times, potentially indicating slower collections and working capital inefficiencies.
From a valuation perspective, Fortis Healthcare’s return on capital employed (ROCE) is 11.9%, and it carries an enterprise value to capital employed multiple of 5.7, which is considered expensive relative to historical peer averages. While the stock currently trades at a discount compared to its peers’ historical valuations, its price-to-earnings growth (PEG) ratio of 2.4 suggests that the market may be pricing in slower profit growth relative to its share price gains. Over the past year, profits have risen by 27.8%, which, although healthy, lags behind the 39.37% return generated by the stock, hinting at stretched valuations.
Holding Fortis Health. from Hospital? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Conclusion: Why the Stock is Falling
In summary, Fortis Healthcare Ltd’s recent share price decline on 09-Mar reflects a combination of short-term technical weakness, reduced investor participation, and valuation concerns despite strong long-term fundamentals. The stock’s underperformance relative to the Sensex and its sector, coupled with trading below key moving averages, signals caution among investors. While the company’s operational growth and institutional support remain solid, elevated debt levels, lower interest coverage, and a stretched valuation multiple are likely weighing on sentiment. Investors appear to be reassessing the risk-reward balance, leading to the current downward pressure on the stock price.
Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →
